Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

EnzymeRx

Request full access

enzymerx.com - Deze website is te koop! - de beste bron van informatie over enzymerx.

Paramus, United StatesFounded 2008Biotechnology

About EnzymeRx

EnzymeRx, LLC operated as a clinical-stage biopharmaceutical firm, established in 2008 with its headquarters in Paramus, New Jersey. The company focused its efforts on developing therapeutic solutions for conditions stemming from hyperuricemia, specifically targeting resistant and refractory gout.

The company's primary undertaking was the development of uricase-PEG 20, a pegylated variant of the uricase enzyme. This product, obtained from *Candida utilis*, was engineered to have a prolonged half-life and diminished immunogenicity. The therapeutic was aimed at patients who were unresponsive to or could not tolerate existing treatments for severe gout. In May 2008, EnzymeRx secured $14 million in a Series A funding round from investors including Pequot Capital Management and FirstMark Capital. This capital injection facilitated the acquisition of worldwide rights (excluding Taiwan) to uricase-PEG 20 from Polaris Pharmaceuticals, which had already advanced the drug through a Phase I clinical trial.

The business strategy centered on advancing uricase-PEG 20 through further clinical trials, with plans for a multi-dose Phase II study in refractory gout patients. The company's President and CEO was Tony Fiorino, MD, PhD. In a strategic move to focus on its core oncology programs, Polaris Pharmaceuticals divested the asset while retaining an equity stake in EnzymeRx. The company's journey as an independent entity concluded on November 29, 2010, when it was acquired by the Chinese biopharmaceutical company 3Sbio for $6.25 million.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
22.0/100
Client focus
B2B

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC May 2008 $14M $56M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

EnzymeRx website traffic

Latest recorded traffic for EnzymeRx is 110 monthly website visits. EnzymeRx's team grew 0% over the past year.

Latest monthly visits110 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

EnzymeRx in the Paramus ecosystem

Live from Dealroom

The EnzymeRx office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Paramus HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about EnzymeRx on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See EnzymeRx’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.